Rodent carcinogenicity profile of the antidiabetic dual PPAR α and γ agonist muraglitazar

Sarah H. Tannehill-Gregg, Thomas P. Sanderson, Daniel Minnema, Richard Voelker, Borge Ulland, Samuel Monroe Cohen, Lora L Arnold, Beth E. Schilling, C. Robbie Waites, Mark A. Dominick

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The carcinogenic potential of muraglitazar, a dual human peroxisome proliferator-activated receptor α/γ agonist, was evaluated in 2-year studies in mice (1, 5, 20, and 40 mg/kg) and rats (1, 5, 30, and 50 mg/kg). Benign gallbladder adenomas occurred at low incidences in male mice at 20 and 40 mg/kg (area under the curve [AUC] exposures ≥ 62 times human exposure at 5 mg/day) and were considered drug related due to an increased incidence of gallbladder mucosal hyperplasia at these doses. There was a dose-related increased incidence of transitional cell papilloma and carcinoma of the urinary bladder in male rats at 5, 30, and 50 mg/kg (AUC exposures ≥ 8 times human exposure at 5 mg/day). At 30 and 50 mg/kg, the urinary bladder tumors were accompanied by evidence of increased urine solids. Subsequent investigative studies established that the urinary bladder carcinogenic effect was mediated by urolithiasis rather than a direct pharmacologic effect on urothelium. Incidences of subcutaneous liposarcoma in male rats and subcutaneous lipoma in female rats were increased at 50 mg/kg (AUC exposures ≥ 48 times human exposure at 5 mg/day) and attributed, in part, to persistent pharmacologic stimulation of preadipocytes. Toxicologically relevant nonneoplastic changes in target tissues included thinning of cortical bone in mice and hyperplastic and metaplastic adipocyte changes in mice and rats. Considering that muraglitazar is nongenotoxic, the observed tumorigenic effects in mice and rats have no established clinical relevance since they occurred at either clinically nonrelevant exposures (gallbladder and adipose tumors) or by a species-specific mechanism (urinary bladder tumors).

Original languageEnglish (US)
Pages (from-to)258-270
Number of pages13
JournalToxicological Sciences
Volume98
Issue number1
DOIs
StatePublished - Jul 1 2007

Fingerprint

Peroxisome Proliferator-Activated Receptors
Hypoglycemic Agents
Rats
Rodentia
Urinary Bladder
Gallbladder
Area Under Curve
Tumors
Incidence
Urinary Bladder Neoplasms
Urothelium
Liposarcoma
Urolithiasis
Transitional Cell Carcinoma
Lipoma
Papilloma
Adipocytes
Adenoma
Hyperplasia
muraglitazar

Keywords

  • Gallbladder adenoma
  • Lipoma
  • Liposarcoma
  • Muraglitazar
  • Peroxisome proliferator-activated receptor (PPAR) agonist
  • Rodent carcinogenicity
  • Urinary bladder carcinogenesis
  • Urolithiasis

ASJC Scopus subject areas

  • Toxicology

Cite this

Tannehill-Gregg, S. H., Sanderson, T. P., Minnema, D., Voelker, R., Ulland, B., Cohen, S. M., ... Dominick, M. A. (2007). Rodent carcinogenicity profile of the antidiabetic dual PPAR α and γ agonist muraglitazar. Toxicological Sciences, 98(1), 258-270. https://doi.org/10.1093/toxsci/kfm083

Rodent carcinogenicity profile of the antidiabetic dual PPAR α and γ agonist muraglitazar. / Tannehill-Gregg, Sarah H.; Sanderson, Thomas P.; Minnema, Daniel; Voelker, Richard; Ulland, Borge; Cohen, Samuel Monroe; Arnold, Lora L; Schilling, Beth E.; Waites, C. Robbie; Dominick, Mark A.

In: Toxicological Sciences, Vol. 98, No. 1, 01.07.2007, p. 258-270.

Research output: Contribution to journalArticle

Tannehill-Gregg, SH, Sanderson, TP, Minnema, D, Voelker, R, Ulland, B, Cohen, SM, Arnold, LL, Schilling, BE, Waites, CR & Dominick, MA 2007, 'Rodent carcinogenicity profile of the antidiabetic dual PPAR α and γ agonist muraglitazar', Toxicological Sciences, vol. 98, no. 1, pp. 258-270. https://doi.org/10.1093/toxsci/kfm083
Tannehill-Gregg, Sarah H. ; Sanderson, Thomas P. ; Minnema, Daniel ; Voelker, Richard ; Ulland, Borge ; Cohen, Samuel Monroe ; Arnold, Lora L ; Schilling, Beth E. ; Waites, C. Robbie ; Dominick, Mark A. / Rodent carcinogenicity profile of the antidiabetic dual PPAR α and γ agonist muraglitazar. In: Toxicological Sciences. 2007 ; Vol. 98, No. 1. pp. 258-270.
@article{4b15d3ae61b143629724bd856e990eb0,
title = "Rodent carcinogenicity profile of the antidiabetic dual PPAR α and γ agonist muraglitazar",
abstract = "The carcinogenic potential of muraglitazar, a dual human peroxisome proliferator-activated receptor α/γ agonist, was evaluated in 2-year studies in mice (1, 5, 20, and 40 mg/kg) and rats (1, 5, 30, and 50 mg/kg). Benign gallbladder adenomas occurred at low incidences in male mice at 20 and 40 mg/kg (area under the curve [AUC] exposures ≥ 62 times human exposure at 5 mg/day) and were considered drug related due to an increased incidence of gallbladder mucosal hyperplasia at these doses. There was a dose-related increased incidence of transitional cell papilloma and carcinoma of the urinary bladder in male rats at 5, 30, and 50 mg/kg (AUC exposures ≥ 8 times human exposure at 5 mg/day). At 30 and 50 mg/kg, the urinary bladder tumors were accompanied by evidence of increased urine solids. Subsequent investigative studies established that the urinary bladder carcinogenic effect was mediated by urolithiasis rather than a direct pharmacologic effect on urothelium. Incidences of subcutaneous liposarcoma in male rats and subcutaneous lipoma in female rats were increased at 50 mg/kg (AUC exposures ≥ 48 times human exposure at 5 mg/day) and attributed, in part, to persistent pharmacologic stimulation of preadipocytes. Toxicologically relevant nonneoplastic changes in target tissues included thinning of cortical bone in mice and hyperplastic and metaplastic adipocyte changes in mice and rats. Considering that muraglitazar is nongenotoxic, the observed tumorigenic effects in mice and rats have no established clinical relevance since they occurred at either clinically nonrelevant exposures (gallbladder and adipose tumors) or by a species-specific mechanism (urinary bladder tumors).",
keywords = "Gallbladder adenoma, Lipoma, Liposarcoma, Muraglitazar, Peroxisome proliferator-activated receptor (PPAR) agonist, Rodent carcinogenicity, Urinary bladder carcinogenesis, Urolithiasis",
author = "Tannehill-Gregg, {Sarah H.} and Sanderson, {Thomas P.} and Daniel Minnema and Richard Voelker and Borge Ulland and Cohen, {Samuel Monroe} and Arnold, {Lora L} and Schilling, {Beth E.} and Waites, {C. Robbie} and Dominick, {Mark A.}",
year = "2007",
month = "7",
day = "1",
doi = "10.1093/toxsci/kfm083",
language = "English (US)",
volume = "98",
pages = "258--270",
journal = "Toxicological Sciences",
issn = "1096-6080",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Rodent carcinogenicity profile of the antidiabetic dual PPAR α and γ agonist muraglitazar

AU - Tannehill-Gregg, Sarah H.

AU - Sanderson, Thomas P.

AU - Minnema, Daniel

AU - Voelker, Richard

AU - Ulland, Borge

AU - Cohen, Samuel Monroe

AU - Arnold, Lora L

AU - Schilling, Beth E.

AU - Waites, C. Robbie

AU - Dominick, Mark A.

PY - 2007/7/1

Y1 - 2007/7/1

N2 - The carcinogenic potential of muraglitazar, a dual human peroxisome proliferator-activated receptor α/γ agonist, was evaluated in 2-year studies in mice (1, 5, 20, and 40 mg/kg) and rats (1, 5, 30, and 50 mg/kg). Benign gallbladder adenomas occurred at low incidences in male mice at 20 and 40 mg/kg (area under the curve [AUC] exposures ≥ 62 times human exposure at 5 mg/day) and were considered drug related due to an increased incidence of gallbladder mucosal hyperplasia at these doses. There was a dose-related increased incidence of transitional cell papilloma and carcinoma of the urinary bladder in male rats at 5, 30, and 50 mg/kg (AUC exposures ≥ 8 times human exposure at 5 mg/day). At 30 and 50 mg/kg, the urinary bladder tumors were accompanied by evidence of increased urine solids. Subsequent investigative studies established that the urinary bladder carcinogenic effect was mediated by urolithiasis rather than a direct pharmacologic effect on urothelium. Incidences of subcutaneous liposarcoma in male rats and subcutaneous lipoma in female rats were increased at 50 mg/kg (AUC exposures ≥ 48 times human exposure at 5 mg/day) and attributed, in part, to persistent pharmacologic stimulation of preadipocytes. Toxicologically relevant nonneoplastic changes in target tissues included thinning of cortical bone in mice and hyperplastic and metaplastic adipocyte changes in mice and rats. Considering that muraglitazar is nongenotoxic, the observed tumorigenic effects in mice and rats have no established clinical relevance since they occurred at either clinically nonrelevant exposures (gallbladder and adipose tumors) or by a species-specific mechanism (urinary bladder tumors).

AB - The carcinogenic potential of muraglitazar, a dual human peroxisome proliferator-activated receptor α/γ agonist, was evaluated in 2-year studies in mice (1, 5, 20, and 40 mg/kg) and rats (1, 5, 30, and 50 mg/kg). Benign gallbladder adenomas occurred at low incidences in male mice at 20 and 40 mg/kg (area under the curve [AUC] exposures ≥ 62 times human exposure at 5 mg/day) and were considered drug related due to an increased incidence of gallbladder mucosal hyperplasia at these doses. There was a dose-related increased incidence of transitional cell papilloma and carcinoma of the urinary bladder in male rats at 5, 30, and 50 mg/kg (AUC exposures ≥ 8 times human exposure at 5 mg/day). At 30 and 50 mg/kg, the urinary bladder tumors were accompanied by evidence of increased urine solids. Subsequent investigative studies established that the urinary bladder carcinogenic effect was mediated by urolithiasis rather than a direct pharmacologic effect on urothelium. Incidences of subcutaneous liposarcoma in male rats and subcutaneous lipoma in female rats were increased at 50 mg/kg (AUC exposures ≥ 48 times human exposure at 5 mg/day) and attributed, in part, to persistent pharmacologic stimulation of preadipocytes. Toxicologically relevant nonneoplastic changes in target tissues included thinning of cortical bone in mice and hyperplastic and metaplastic adipocyte changes in mice and rats. Considering that muraglitazar is nongenotoxic, the observed tumorigenic effects in mice and rats have no established clinical relevance since they occurred at either clinically nonrelevant exposures (gallbladder and adipose tumors) or by a species-specific mechanism (urinary bladder tumors).

KW - Gallbladder adenoma

KW - Lipoma

KW - Liposarcoma

KW - Muraglitazar

KW - Peroxisome proliferator-activated receptor (PPAR) agonist

KW - Rodent carcinogenicity

KW - Urinary bladder carcinogenesis

KW - Urolithiasis

UR - http://www.scopus.com/inward/record.url?scp=34447547778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447547778&partnerID=8YFLogxK

U2 - 10.1093/toxsci/kfm083

DO - 10.1093/toxsci/kfm083

M3 - Article

C2 - 17426106

AN - SCOPUS:34447547778

VL - 98

SP - 258

EP - 270

JO - Toxicological Sciences

JF - Toxicological Sciences

SN - 1096-6080

IS - 1

ER -